Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:41:45.502Z.
Calculation as of: 2026-10-06T15:41:45.502Z.
Quote observation: 2026-10-06T15:40:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340
PE RATIO
N/A
Market Cap
$490.16M
PE Ratio
18.66
TTM Avg
12.02
3Y Avg
15.67
5Y Avg
102.65
Market Cap
$473.83M
PE Ratio
N/A
TTM Avg
16.90
3Y Avg
16.90
5Y Avg
16.90
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $491.69M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $490.16M | 18.66 | 12.02 | 15.67 | 102.65 |
| Arvinas, Inc. (ARVN)vs › | $482.53M | 46.74 | 54.09 | 54.09 | 54.09 |
| Oculis Holding AG (OCS)vs › | $501.67M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $479.89M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $474.59M | N/A | 20.76 | 20.76 | 20.76 |
| Contineum Therapeutics, Inc. (CTNM)vs › | $473.83M | N/A | 16.90 | 16.90 | 16.90 |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.83M | N/A | N/A | N/A | N/A |
| Kamada Ltd. (KMDA)vs › | $468.45M | 21.42 | 21.78 | 26.84 | 31.34 |
| 908 Devices Inc. (MASS)vs › | $514.53M | N/A | 12.07 | 12.07 | 12.07 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$7.47
Forward EPS (Est.)
$-0.05
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
